A 12-Week, Phase 2, Multicenter, Randomized, Double-Masked, Vehicle Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate the Efficacy and Safety of DFL24498 0.08% Topical Ophthalmic Solution Versus Vehicle in Participants With Dry Eye Disease
Latest Information Update: 06 Apr 2026
At a glance
- Drugs Isocyclosporin A (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Dompe Farmaceutici
Most Recent Events
- 06 Apr 2026 New trial record